Munisamy Malathi, Devinder Mohan Thappa
Department of Dermatology and STD, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India

Correspondence Address:
Devinder Mohan Thappa
Professor and Head, Department of Dermatology and STD, JIPMER, Pondicherry - 605 006
India

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/0019-5154.108029

Abstract

Leprosy has been considered a curable disease after the implementation of multidrug therapy (MDT), which has been proven to be safe and effective, by bringing about a significant change in the global and national scenario of leprosy by upgrading the control of leprosy to the next stage of eradication. Since its introduction, the MDT regimens for the treatment of leprosy have undergone several changes especially with regard to the duration of treatment. The advantages of shortened duration of treatment need to be balanced against the risk of relapse and a lot of controversies exist pertaining to this aspect. The fixed-duration (FD) therapy is not popular among academicians and private practitioners who prefer precise diagnosis and treatment with superior MDT regimens and for a longer duration. On the contrary, from a public health-care point of view, precise diagnosis and a longer treatment schedule are not cost effective and not feasible to be implemented in elimination programs. Hence, a fine balance needs to be maintained between achieving a cure for the patient and protecting the society at risk, and this review discusses the various limitations and opportunities of FD therapy with a note on the newer MDT regimens.

Keywords: Fixed duration, leprosy, multibacillary, multidrug therapy, paucibacillary

What was known?
Since its introduction, the multidrug therapy (MDT) regimens for the treatment of leprosy have undergone several changes especially with regard to the duration of treatment. The advantages of shortened duration of treatment need to be balanced against the risk of relapse and a lot of controversies exist pertaining to this aspect. The fixed duration (FD) therapy is not popular among academicians and private practitioners who prefer precise diagnosis and treatment with superior MDT regimens and for a longer duration.

Introduction

Global and Indian Scenario

History of MDT

• To address resistance to dapsone and to discourage resistance to other drugs to be used.
• To promote compliance and to move away from long-term monotherapy such as dapsone.
• To retain rifampicin in all therapeutic regimens because of its powerful bactericidal action and its effectiveness even when taken once a month.
• To promote compliance and cost effectiveness.

• 1982-1985: Introduction of MDT on a global basis.
• 1986-1990: Expansion of MDT (into the 'less difficult' areas).
• 1991-1999: Elimination strategy.
• 2000 onward: A fourth period, planned to last six years, designated for the 'Intensive elimination strategy' or the 'Final push'.

Table 1: Classification of paucibacillary and multibacillary leprosy and MDT regimens: Changes over time Click here to view

Differences in Classification of Leprosy Cases and MDT Implementation in India

• PB: 1-5 skin lesions, no nerve or only one nerve with or without 1-5 skin lesions, slit-skin smears negative at all sites.
• MB: ≥6 skin lesions, more than one nerve irrespective of the number of skin lesions, slit-skin smears positive at any site irrespective of the number of skin lesions or nerves.

FD MDT Regimens

Advantages of FD MDT

• The modifications in the definitions of PB/MB cases over time have resulted in the misclassification of many cases. There is an increased proportion of MB cases among newly detected cases due to the classification of cases that would otherwise be PB leprosy. Thus, the bacterial load of the majority of currently diagnosed MB patients is significantly lesser than those in the past as also estimated by the WHO wherein the newly detected cases with high bacillary indices (BI ≥ 3) are less than 15%. ^[15] The net result would be a decrease in the overall requirements of chemotherapy for MB leprosy.
• The rates of relapse among MB cases after 12 months of MDT, as estimated by the routine control programs as well as the research projects were very low, about 0.2% annually, similar to those observed after 24 months of MDT. ^[16] Nevertheless, higher rates of relapse have been reported in some studies ^[17],[18] involving MB patients with a high initial bacillary index (BI) (average BI ≥ 4+). But, such patients are only a minority in the current scenario of the widespread use of MDT, and hence the relapses contributed by them will be small.
• The dapsone-clofazimine combination is highly bactericidal as observed from nude mouse experiments and clinical trials wherein daily treatment with this combination killed more than 99.999% of viable Mycobacterium leprae in 3-6 months. Thus, this combination ensures the effective elimination of the spontaneously occurring rifampicin-resistant mutants which are usually not more than 10 ^[4] organisms in an untreated lepromatous leprosy (LL) case. ^[16]
• According to some studies [Steering Committee on Chemotherapy of Mycobacterial Diseases (THEMYC) and clinical trial in Malawi], the response of MB cases receiving fewer than the standard 24 doses of MDT was as promising as those receiving 24 doses or more. ^{[16],[19],[20]}
• A retrospective study done on the clinical and bacteriological progress of defaulted MB cases revealed that treatment with less than 12 months of MDT still had favorable therapeutic effects among the majority of MB patients. ^[21]
• Four WHO-sponsored studies to evaluate the efficacy of a variety of drug combinations and treatment periods have found that even though the bacillary load was reduced, a positive BI was still present at the end of 24 or 12 months. But these bacteria were no longer found to be viable as confirmed by mouse footpad inoculation. Moreover, as the immune system of MB cases is grossly deficient to mount an effective defense against M. leprae, the clearance of bacilli from the body becomes a slow process. It has also been observed that although BIs remained positive at the end of the treatment, they gradually declined during follow-up, tending to confirm that bacillary clearance is not affected by prolonging the intake of drugs. Considering these facts, it is possible to stop MDT safely despite a positive BI after a fixed duration of 24 or 12 months. Now, the problem lies in determining the exact duration of MDT to achieve maximum results for MB cases. ^{[20],[22],[23]}
• Operationally, a long duration of treatment is a major obstacle to successful implementation of MDT. Thus, a reduction in the length of treatment without jeopardizing effectiveness would potentially facilitate patient compliance and national program activities especially in remote rural areas where medical care is often scarce and frequently inaccessible to most patients. ^[20]
• By shortening the duration of MDT to 12 months, the disadvantages of reduced duration are likely to be minimal and even an occasional relapse or failure of treatment can be treated with the same regimen, as the relapse is due to drug-sensitive persisters. ^[24]

• Though continued visibility of clinically active patches exist in a proportion of patients at the end of six months of therapy, this persisting activity is attributed to the continued inflammatory response of the system to clear the persisting killed mycobacteria, fragments, or antigens. It has been observed that, on follow-up, in 30 to 80% of these patients, the clinical activity gradually comes down and the patients get cured. ^[25]

Disadvantages of FD MDT

• It has been proved in a few studies that despite two years of regular therapy, 10% of the patients continue to harbor viable persisters. In addition, incomplete killing of M. leprae in patients treated for two years has been confirmed by the demonstration of ATP in 19% of the bacterial suspensions from skin biopsies and the presence of viable bacilli in the nerves of one-third of the patients as tested by the mouse footpad. These observations signify the persistence of viable drug-sensitive bacilli, probably the dormant bacilli that have escaped the bactericidal effect of drugs including rifampicin in a proportion of patients. The fate of these organisms is of prime importance because there is no evidence that MDT knocks down persisters and there is no drug for leprosy that is known to act on dormant organisms. Moreover, lepromatous patients with high initial BI have naturally a poor cell-mediated immunity (CMI) and poor macrophage functioning to deal with these remaining organisms. Hence, treatment cannot be stopped after one or two years, as persisters are likely to grow, resulting in relapse. But, it may take a much longer time than the incubation period of disease, because clofazimine remains in the tissues for a long duration and maintains a check on the growth of M. leprae.^{[25],[26],[27]}
• Higher rates of relapse of almost 39% have been reported in a subgroup of patients with a large bacterial load (BI ≥ 4+) treated with 24 months of standard MDT, during later years of follow-up in studies where long follow-up has been done. ^[28] It has been observed that higher the BI or shorter the duration of therapy, the higher the risk of relapse. ^[28] In a study by Girdhar, et al., ^[29] the rate of relapse in patients treated with MDT till they were smear negative was 1.1 per 100 person-years, whereas patients on FD MDT showed a relapse rate of 2.04 per 100 person-years. Similarly, the Marchoux Chemotherapy Study Group observed a relapse rate of 3.4 per 100 person-years with FD MDT. ^[30]
• It has been observed that the bacteriological relapses occurred earlier than clinical worsening and this could not be picked up in many studies with a short follow-up period as slit-skin smear is not routinely being used in the fields. ^[25]
• There is also a difference noted in the rates of relapse based on whether they were field studies or institutional studies. This could be attributed to the following differences: Inclusion of all MB cases in the field studies in contrast to mainly LL/BL (BL: Borderline lepromatous) cases in the institutional studies and more regular as well as long-duration follow-up with periodic clinical and skin smear examination in institutional studies. ^[25]
• The endpoint of treatment of pure neuritic leprosy is difficult to establish due to the highly controversial assessment and cure criteria. It has been shown that several patients show advanced disease and are positive for AFB on histology both in the nerves and in skin, even when one or few nerves are clinically affected. This suggests that it would be better to include these patients in the MB group and give a three-drug combination. The national program recommends that when upto one nerve trunk is thickened, the patients could be treated as PB, whereas those with a large number of affected nerves should receive MB therapy. These recommendations seem justified from the point of view of control, as in these patients bacilli are deep in the skin or nerves and are not discharged for transmission. However, what happens in the long run is not clear as all the organisms may not get killed with the limited treatment and may result in the deterioration of the nerve function. Further, despite adequate treatment, in some cases the nerve function can worsen on account of fibrosis, causing concern. ^[25]
• The cost of treating either all or a targeted subpopulation of MB cases with MDT for a prolonged period or carefully following the same sort of patients for a decade might seem high initially, but might not be excessive. Nevertheless, this needs to be weighed against the lower costs of retreatment of the relapses with a second course of MDT, assuming that there is neither the development of drug-resistant disease nor the development of additional disability in relapse cases. ^[28]

• The cure or endpoint of treatment of PB cases (smear-negative patients) has been more difficult to define unlike in MB cases wherein the slit-skin smears are indicators of disease activity. ^[31]
• Continued visibility of a clinically active patch in a proportion of patients at the end of six months of therapy has been observed in almost all studies varying from 10 to 67%. Studies conducted in the institutions have shown a larger proportion of patients who are still active as compared to field situations. ^[25]
• When the length of duration of treatment is not long enough for the body to clear out the bacteria, continued inflammatory response results in persistent clinical activity for up to 12-18 months. There is a delayed resolution in a significant number of patients which sometimes may turn out to be failures of treatment. It has also been observed in a few studies that if diamino diphenyl sulphone (DDS) is continued for a further period of six months or MDT is administered for 12 months instead of the recommended six months, the proportion of patients staying active could be significantly reduced. ^[25]
• In several reports, active granuloma has been found in over 50% of the patients on completion of therapy and even six months later, suggesting persisting disease activity. ^[25]
• Studies at the Central JALMA Institute of Leprosy (CJLI), Agra, India have shown that a good number of patients diagnosed as PB leprosy clinically were acid-fast (AFB) bacilli positive in the skin smear, indicating their chances of getting inadequate treatment and these patients would be prone for relapse. ^[31]

Solutions to Overcome These Problems

• MB cases with an initial average BI ≥ 4+ should receive at least four years of standard WHO MDT as proposed by the Marchoux chemotherapy study group. ^[30]
• Though most of the patients with high BI continue to improve after the completion of the 12-month regimen, an additional 12 months of MDT for MB leprosy may be required for patients showing evidence of deterioration. ^[32]
• The addition of immunotherapy by the Bacillus Calmette-Guérin (BCG) or Mycobacterium welchii vaccine can help to reduce the duration of treatment by 50%. ^[33]
• A regimen of one year with the addition of ofloxacin and minocycline at a monthly dose to the existing MDT can be carried out in an attempt to reduce the duration of therapy as per the trials conducted by the NLEP and CJLI. ^[34]
• Rigorous annual follow-up for at least five years and even more for PB cases and 10 years and even more for MB cases after being released from FD MDT is essential. ^[24]
• Ofloxacin and minocycline with potent bactericidal activity against M. leprae can provide an effective single-dose therapy for PB leprosy when combined with rifampicin as ROM (R: Rimfanpicin, O: Ofloxacin, M: Minocycline) regimen. For MB leprosy, 24 monthly doses (pulsed) of supervised ROM can be advocated for patients refusing or unable to take MDT. ROM is found to be as safe and effective as MDT during dosing, causing no skin pigmentation, and conferring similar clinical, bacteriologic, and histologic improvements, without increased rates of lepra reactions. However, ROM costs four times more than MDT for similar duration regimens, prohibiting mass administration, but patients treated with ROM may remain anonymous to the community and even their families. ^[35]
• The significance of abundant AFB- and MB-type histopathology in patients grouped as PB leprosy should be resolved so that these patients could be given the drug therapy and the duration of therapy they warrant. The techniques that directly evaluate the type and severity of leprosy should be made relevant to the treatment, especially in centers where they are available. ^[36]
• As the workload and financial burden on leprosy organizations has significantly decreased over the years with substantial decrease in the number of leprosy patients, slit-skin smears may again be made an integral part of the leprosy program.

Newer MDT Regimens

• The longer duration of therapy for MB leprosy is a disadvantage from the operational point of view.
• Daspone and clofazimine are only weakly bactericidal against M. leprae, and as these weaker drugs determine the minimal effective duration of the current regimen, further shortening of the duration of treatment might result in higher rates of relapse.
• Daily administration of dapsone and clofazimine are not directly supervised.
• Side effects of the drugs in the current regimen like clofazimine-induced disoloration of skin, hypersensitivity to dapsone, rifampicin-induced hepatitis, and so on.
• Emergence of resistance to dapsone and rifampicin.

1. Rifampicin-susceptible MB patient: ^[40]
   • Fully supervisable, monthly administered regimen rifapentine 900 mg (or rifampicin 600 mg) plus moxifloxacin 400 mg plus clarithromycin 1000 mg (or minocycline 200 mg) administered once monthly under supervision for 12 months.
2. Rifampicin-resistant MB patient: Fully supervised regimen in two phases: ^[41]
   • An initial six-month intensive phase followed by an 18-month continuation phase. The intensive phase: Moxifloxacin 400 mg-clofazimine 50 mg-clarithromycin 500 mg-minocycline 100 mg all taken daily.
   • The continuation phase: Moxifloxacin 400 mg-clarithromycin 1000 mg-minocycline 200 mg all taken once monthly.
   • Intensive phase: Daily administration of 50 mg clofazimine, together with two of the following drugs: 400 mg ofloxacin, 100 mg minocycline, or 500 mg clarithromycin for six months.
   • Continuation phase: Daily administration of 50 mg clofazimine, together with 100 mg minocycline or 400 mg ofloxacin for an additional 18 months.
   • If available, ofloxacin may be replaced by moxifloxacin 400 mg, which has stronger bactericidal activity against M. leprae.^[42]
3. Fully supervisable, monthly administered regimens:
   • ROM combination: Rifampicin 600 mg, ofloxacin 400 mg, and minocycline 100 mg for 12 months. ^[43]
   • PMM combination: Rifapentin 600 mg, moxifloxacin 400 mg, minocycline 100 mg (PMM) for 12 months. ^[40]
4. Six-week quadruple regimen: Rifampicin 600 mg plus ofloxacin 400 mg plus clofazimine 100 mg plus minocycline 100 mg once a week for six weeks. ^[44]
5. Once a month, supervised rifampicin 600 mg plus ofloxacin 400 mg plus minocycline 100 mg in addition to self-administered dapsone 100 mg plus clofazimine 50 mg daily for 12 months. ^[45]
6. Daily rifampicin 600 mg plus sparfloxacin 200 mg plus clarithromycin 500 mg plus minocycline 100 mg for 12 weeks. ^[46]

• Single dose of ROM or RMM for all PB cases. ^[11],[43]
• Four-week, ofloxacin-containing regimen: Rifampicin 600 mg and ofloxacin 400 mg given in supervised doses daily for four weeks.
• Once a month ROM for six months.

Accompanied MDT

Uniform MDT

• The uniform MDT (U-MDT) regimen could be effective and operationally convenient in the context of the integration of leprosy into general health-care services. ^[48]
• Drug compliance with a shorter duration can make it an acceptable regimen for MB patients.
• Clofazimine-related pigmentation of the skin is usually short lived and acceptable to PB patients.
• As continued inflammatory response results in persistent activity in leprosy, addition of clofazimine can help in PB patients.
• Granulomas regressed faster if clofazimine was added to the PB regimen.

• U-MDT will overtreat PB leprosy patients and undertreat MB patients, especially those with a high initial BI.

Conclusions

References

1.	WHO. Leprosy today. Available from: http://www.who.int/lep/en/. [Last assessed on 2012 Aug 05].
2.	India's alarming share of global new leprosy cases. Available from: http://www.thehindu.com/sci-tech/science/article2995018.ece. [Last assessed on 2012 Aug 05].
3.	Desikan KV. Elimination of leprosy and possibility of eradication: The Indian scenario. Indian J Med Res 2012;135:3-5.   [PUBMED]
4.	Daumerie D. Implementation of MDT-Successive steps. In: Sansarricq H, editor. Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: WHO Library Cataloguing-in-Publication Data; 2004. p. 45-57.
5.	WHO Study Group. Chemotherapy of leprosy. WHO Technical Report Series no. 847. Geneva: World Health Organization; 1994.
6.	Sansarricq H. The Study Group. In: Sansarricq H, editor. Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: WHO Library Cataloguing-in-Publication Data; 2004. p. 45-57.
7.	Jopling WH, McDougall AC. Handbook of leprosy, 5 th ed. New Delhi: CBS Publishers and Distributors; 1996. p. 101-17.
8.	Dharmendra. Classifications of leprosy. In: Hastings RC, Opromolla DVA, editors. Leprosy, 2 nd ed. Edinburgh: Churchill Livingstone; 1994. p. 179-90.
9.	Jacobson RR. Treatment of leprosy. In: Hastings RC, Opromolla DV, editors. Leprosy, 2 nd ed. Edinburgh: Churchill Livingstone; 1994. p. 317-49.   [PUBMED]
10.	Rao CK. Implementation of WHO MDT in India 1982-2001. In: Sansarricq H, editor. Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: WHO Library Cataloguing-in-Publication Data; 2004. p. 92-105.
11.	Pai VV, Ganapathi R, Rao R. Development and evolution of WHO MDT and newer treatment regimens. In: Kar HK, Kumar B, editors. IAL textbook of leprosy. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2010. p. 353-67.
12.	Mishra RS, Kumar J. Classification. In: Kar HK, Kumar B, editors. IAL textbook of leprosy. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2010. p. 144-51.
13.	WHO recommended MDT regimens. Available from: http://www.who.int/lep/mdt/regimens/en/index.html. [Last assessed on 2012 Aug 05].
14.	Worobec SM. Treatment of leprosy/Hansen's disease in the early 21 st century. Dermatol Ther 2009;22:518-37.   [PUBMED]
15.	MDT: Duration of treatment FAQ. Available from: http://www.who.int/lep/mdt/duration/en/inde×2.html. [Last assessed on 2012 Aug 05].
16.	Ji B. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Lepr Rev 1998;69:106-9.   [PUBMED]
17.	Shaw IN, Christian M, Jesudasan K, Kurian N, Rao GS. Effectiveness of multidrug therapy in multibacillary leprosy: A long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity. Lepr Rev 2003;74:141-7.   [PUBMED]
18.	Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: Effect of length of therapy. Lepr Rev 2000;71:144-53.   [PUBMED]
19.	Pönnighaus JM, Boerrigter G. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Int J Lepr Other Mycobact Dis 1995;63:1-7.
20.	Sales AM, Sabroza PC, Nery JA, Dupprè NC, Sarno EN. No difference in leprosy treatment outcomes comparing 12- and 24-dose multidrug regimens: A preliminary study. Cad Saude Publica 2007;23:815-22.
21.	Shetty VP, Wakade AV, Ghate SD, Pai VV, Ganapati RR, Antia NH. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. Lepr Rev 2005;76:241-52.
22.	Pattyn SR, Bourland J, Grillone S, Groenen G, Ghys P. Combined regimens of one year duration in the treatment of multibacillary leprosy-Combined regimens with rifampicin administered during one year. Lepr Rev 1989;60:109-17.
23.	Pattyn SR. Efficacy of different regimens in multibacillary leprosy. Lepr Rev 1986;57:265-71.
24.	Pai VV. Chemotherapy of leprosy-further challenges. Available from: http://medind.nic.in/haa/t06/i2/haat06i2p72.pdf. [Last assessed on 2012 Aug 05].
25.	Girdhar BK, Girdhar A. Short course treatment of leprosy: Present status. Available from: http://icmr.nic.in/bufeb02.pdf. [Last assessed on 2012 Aug 05].
26.	Anonymous. Persisting Mycobacterium leprae among THELEP trial patients in Bamako and Chingleput. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Lepr Rev 1987;58:325-37.
27.	Sharma A, Sharma VK, Rajwanshi A, Das A, Kaur I, Kumar B. Presence of M. leprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR. Lepr Rev 1999;70:281-6.
28.	Lemaster JW, Shwe T, Butlin CR, Roche PW. Prediction of 'highly skin smear positive' cases among MB leprosy patients using clinical parameters. Lepr Rev 2001;72:23-8.
29.	Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: Effect of length of therapy. Lepr Rev 2000;71:144-53.
30.	Jamet P, Ji B. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis 1995;63:195-201.
31.	Prasad PV, Babu A, Kaviarasan PK, Viswanathan P, Tippoo R. MDT-MB therapy in paucibacillary leprosy: A clinicopathological assessment. Indian J Dermatol Venereol Leprol 2005;71:242-5.   [PUBMED]
32.	Leprosy elimination: MDT: Duration of treatment FAQ. Available from: http://www.who.int/lep/mdt/duration/en/inde×1.html. [Last assessed on 2012 Aug 05].
33.	Sehgal VN, Sardana K. Immunoprophylaxis of leprosy: Current status and future prospects. Indian J Dermatol Venereol Leprol 2007;73:71-2.   [PUBMED]
34.	Katoch K, Katoch VM, Natarajan M, Gupta UD, Sharma VD, Singh HB. Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT+once a month Minocycline and Ofloxacin. Indian J Lepr 2008;80:331-44.
35.	Villahermosa LG, Fajardo TT Jr, Abalos RM, Cellona RV, Balagon MV, Dela Cruz EC, et al. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Am J Trop Med Hyg. 2004;70:197-200.
36.	Rao PN, Pratap D, Ramana Reddy AV, Sujai S. Evaluation of leprosy patients with 1 to 5 skin lesions with relevance to their grouping into paucibacillary or multibacillary disease. Indian J Dermatol Venereol Leprol 2006;72:207-10
37.	Prasad P, Kaviarasan PK. Leprosy therapy, past and present: Can we hope to eliminate it? Indian J Dermatol 2010;55:316-24.   [PUBMED]
38.	Bandit C. Recent Advances in Leprosy Chemotherapy. J Trop Med Parasitol 2006;29:68-76.
39.	Ji B. Chemotherapy and chemoprophylaxis of leprosy. Available from: http://www.tropika.net/review/020226-Leprosy_Chemotherapy/article.pdf. [Last assessed on 2012 Aug 05].
40.	Ji B, Grosset J. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev 2000;71:S81-7.
41.	Report of the ninth meeting of the WHO technical advisory group on leprosy control. World Health Organization, Regional Office for South-East Asia, 2008.
42.	WHO Expert Committee on Leprosy. WHO Technical Report Series 968, 2012.
43.	LEPROSY-NEW DRUG REGIMENS. Available from: http://www.who.int/tdr/research/progress/9900/methods_treatment/en/inde×5.html. [Last accessed on 2012 Aug 05].
44.	Pattyn S, Grillone S. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. Lepr Rev 2002;73:245-7.
45.	Katoch K, Katoch VM, Natrajan M, Sharma VD, Singh HB, Gupta UD. Chemotherapy trials in MB leprosy using conventional and newer drugs pefloxacin and minocycline. Indian J Dermatol Venereol Leprol 2000;66:18-25.   [PUBMED]
46.	Tejasvi T, Khaitan BK, Khanna N, Pandhi RK, Singh MK. Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy. Indian J Lepr 2006;78:329-37.
47.	Ji B. Accompanied MDT (AMDT)-more questions than answers. Lepr Rev 2002;73:301-7.
48.	Ji B, Saunderson P. Uniform MDT (U-MDT) regimen for all leprosy patients-another example of wishful thinking. Lepr Rev 2003;74:2-6.

What is new?
The duration of MDT required depends on the aim, resources, motivation of the individual, and his availability for follow up. In the field setup, where the aim is to interrupt the transmission of leprosy, a fixed duration of 24 or 12 months with three drug MDT for MB patients is likely to do the job. On the other hand, for the institutional patients, where the aim is the cure of the individual patient in addition to the interruption of transmission, an extended treatment of four years or until smear negativity is desirable for all highly bacillated patients with BI > 4+.